CAS: 58438-03-2; (S)-2-Amino-3-(Naphthalen-2-yl)Propanoic Acid

相似化合物

76985-09-6 112883-43-9 138774-94-4

上下游产品

(S)-N-acetyl-3-(2-naphthyl)alanine glycine 2-bromomethylnaphthyl bromide (S)-methyl 2-amino-3-(naphthalen-2-yl)propanoate methyl (S)-2-amino-3-(naphthalen-2-yl)propanoate hydr°Chloride N-tert-butoxycarbonyl-3-(2-naphthyl)-L-alanine (3S,4S)-3-[(tert-butyl)dimethylsiloxy]-5-(2-naphthyl)-4-[N-(2-nitrobenzenesulfonyl)amino]pent-1-ene (5S,6S)-1-[4-(tert-butoxycarbonylamino)butyl]-5,6-dihydro-5-diphenylphosphoryloxy-6-[(2-naphthyl)methyl]pyridin-2-one

(E)-3-(萘-2-基)丙烯酸置于二氧化碳,Phenylalanine Ammonia-Lyase From Petroselinum Crispum F137V Double Mutant,氨体系中,化学反应 20.0H,以61%的收率获得产物l-3-(2-萘基)-丙氨酸
参考文献:定制的petroselinum Crispum苯丙氨酸氨化酶突变体,用于合成大体积的l-和d-芳基丙氨酸
标题:定制的petroselinum Crispum苯丙氨酸氨化酶突变体,用于合成大体积的l-和d-芳基丙氨酸
摘要:创建了量身定制的来自petroselinum Crispum(pc Pal)的苯丙氨酸解氨酶突变体,并测试了对各种空间需求的非天然苯丙氨酸类似物的氨消除作用,以及在将氨加成反应到相应的(e)-芳基丙烯酸酯中的过程.在与底物面板所有成员的两个反应中,野生型pc Pal均呈惰性或转化非常差.残基f137和高度保守的残基i460的适当单突变导致pcpal变体具有消除氨气的活性,但向庞大的基质上添加氨气的活性仍然很差.但是,除了经过充分研究的f137外,涉及i460的组合突变还导致了在氨添加方面也具有活性的突变体.协同的多重突变导致pc Pal的底物范围大大扩展,并开辟了新的生物催化路线,用于合成有价值的苯丙氨酸类似物的两种对映体,例如(4-甲氧基苯基)-,(萘甲基-2-基)-,([1,1'-联苯]-4-基),(4'-氟-[1,1'-联苯]-4-基)-和(5-苯基噻吩-2-基)丙氨酸.
DOI:10.1002/cctc.201800258

专利信息

专利号:US-12188072-B2
优先权日:2018-03-19
标题 :Compositions and methods for rapid in vitro synthesis of bioconjugate vaccines in vitro via production and N-glycosylation of protein carriers in detoxified prokaryotic cell lysates
发明人：JEWETT MICHAEL CHRISTOPHER; STARK JESSICA CAROL; DELISA MATTHEW P; JAROENTOMEECHAI THAPAKORN
权利人:UNIV NORTHWESTERN; UNIV CORNELL
摘要:Disclosed are methods, systems, components, and compositions for cell-free synthesis of glycosylated carrier proteins. The glycosylated carrier proteins may be utilized in vaccines, including anti-bacterial vaccines. The glycosylated carrier proteins may include a bacterial polysaccharide conjugated to a carrier, which may be utilized to generate an immune response in an immunized host against the polysaccharide conjugated to the carrier. The glycosylated carrier proteins may be synthesized in cell-free glycoprotein synthesis (CFGpS) systems using prokaryote cell lysates that are enriched in components for glycoprotein synthesis such as oligosaccharyltransferases (OSTs) and lipid-linked oligosaccharides (LLOs) including OSTs and LLOs associated with synthesis of bacterial O antigens.

专利号:US-12365930-B2
优先权日:2016-07-14
标题:Method for rapid in vitro synthesis of glycoproteins via recombinant production of N-glycosylated proteins in prokaryotic cell lysates
发明人：JEWETT MICHAEL CHRISTOPHER; STARK JESSICA CAROL; DELISA MATTHEW P; JAROENTOMEECHAI THAPAKORN
权利人:UNIV NORTHWESTERN; UNIV CORNELL
摘要:Disclosed are methods, systems, components, and compositions for cell-free synthesis of glycosylated proteins. The glycosylated proteins may be utilized in vaccines, including anti-bacterial vaccines. The glycosylated proteins may include a bacterial polysaccharide conjugated to a carrier, which may be utilized to generate an immune response in an immunized host against the polysaccharide conjugated to the carrier. The glycosylated proteins may be synthesized in cell-free glycoprotein synthesis (CFGpS) systems using prokaryote cell lysates that are enriched in components for glycoprotein synthesis such as oligosaccharyltransferases (OSTs) and lipid-linked oligosaccharides (LLOs) including OSTs and LLOs associated with synthesis of bacterial O antigens.

专利号:WO-2024012791-A1
优先权日:2022-07-11
标题 :Electrochemical synthesis of pyrazolines and pyrazoles
发明人：BÄR ROBIN MAXIMILIAN; FORD MARK JAMES; KALDAS SHERIF JAMES; WALDVOGEL SIEGFRIED; HOFMANN SILJA; LINDEN MARTIN
权利人:BAYER AG
摘要:The present invention relates to an electrochemical process for the synthesis of pyrazolines and pyrazoles of formula (I). The process can be especially used for the synthesis of the herbicide safener mefenpyr-diethyl.

专利号:WO-2023019298-A1
优先权日:2021-08-20
标 题:Improved method of synthesis of 1-(3',4'-methylene dioxyphenyl)-2-(methylamino) propane (mdma)
发明人：O'MALLEY WILLIAM IAN; WYNNE PAUL MICHAEL
权利人:MIND MEDICINE AUSTRALIA LTD
摘要:The present invention relates to an improved method of synthesis of 1-(3',4'-methylenedioxyphenyl)-2-(methylamino)propane (MDMA) that is of sufficient purity that it can be used for pharmaceutical applications. In particular the present invention provides a method of synthesising MDMA comprising the steps of (a) condensation of piperonal and nitroethane in the presence of a catalysing base to form 1-(3',4'-methylenedioxyphenyl)-2-nitroprop-1-ene (MDP-2-nitropropene), (b) oxidative hydrolysis of MDP-2-nitropropene to form 1-(3',4'methylenedioxyphenyl)-propan-2-one (MDP2P), and (c) reductive amination of MDP2P to 1-(3',4'-methylenedioxyphenyl)-2-(methylamino)propane (MDMA).

专利号:US-2007088174-A1
优先权日:2005-10-19
标 题 :Synthesis of phenoxyacetic acid derivatives
发明人：WINTER ERIC; REICHEL CARSTEN; GUTHEIL DIETER
权利人:BOEHRINGER INGELHEIM INT
摘要:The present invention relates to an improved process for the preparation of substituted 2-(4-carbonylmethoxy-optionally 2,5-disubstituted-phenyl)-acetaldehydes, in particular 2-(4-alkoxycarbonylmethoxy-optionally 2,5-disubstituted-phenyl)-acetaldehydes and their use in the synthesis of optionally substituted 2-[4-[2-[[-2-hydroxy-2-(4-hydroxyphenyl)-1-methylethyl]-amino]ethyl]-optionally 2,5-disubstituted-phenoxy]acetic acid derivatives or the salts thereof, which may be used as pharmaceutically active substances.

专利号:WO-2025108921-A1
优先权日:2023-11-22
标 题 :Synthesis of radiopharmaceutical agents
发明人：AUZELOUX PHILIPPE; LEVESQUE SOPHIE; GALMIER MARIE-JOSÈPHE; CHEZAL JEAN-MICHEL
权利人:INST NAT SANTE RECH MED; UNIV CLERMONT AUVERGNE; CENTRE LUTTE CONTRE LE CANCER
摘要:Synthesis of radiopharmaceutical agents It is disclosed a method to synthesize a compound of formula (I), or a pharmaceutically acceptable salt thereof: Formula (I), (I) said process comprising contacting a trialkylstannane precursor of formula (II), or a pharmaceutically acceptable salt thereof: Formula (II), (II) with an alkali metal salt of a radionuclide selected from the group consisting of 123I, 124I, 125I, 131I, 211At, in appropriate acidic conditions and in presence of a peroxide ROOH in an 10 appropriate concentration. Said method is particularly suited for synthesizing [131I]N-(2- diethylaminoethyl)-6-iodoquinoxaline-2-carboxamide, providing a notable reduction in the quantity of side products, allowing a much purer finished product, while making use of reagents which are adapted to the constraints which need to be met when developing a product for clinical use and, more in particular, to the constraints to be met in order to 15 adapt the process for being fully automated.